Core Points - The company held its 22nd meeting of the 7th Board of Directors on July 11, 2025, with all 9 directors present [1] - The meeting approved several resolutions, including amendments to the company's articles of association and internal control systems [2][3][4][5] Group 1: Board Meeting Proceedings - The meeting was convened in accordance with relevant laws and regulations, with all directors participating either in person or via telecommunication [1] - The board approved the proposal to amend the articles of association, eliminating the supervisory board and transferring its powers to the audit committee [2] - The board also approved the revision of the "Three Major One Big" collective decision-making implementation measures [3] Group 2: Internal Control and Governance - The board approved amendments to various internal control systems, including the rules for shareholder meetings and board meetings [4][5] - The board agreed to revise the dividend return plan for shareholders following the initial public offering [5] - The board approved the performance evaluation results for the management team for the year 2024 [5] Group 3: Board Member Nominations - The board nominated candidates for the 8th Board of Directors, including both non-independent and independent directors, with terms lasting three years [6][7] - The independent director candidates must pass the Shenzhen Stock Exchange's review before being submitted for shareholder approval [7] Group 4: Upcoming Shareholder Meeting - The board scheduled the first extraordinary general meeting of 2025 for July 28, 2025 [10]
登康口腔: 第七届董事会第二十二次会议决议公告